Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QN-019a
- Development stage
- Phase 1
- Lead developer
- Qihan Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
QN-019a is an allogeneic cell therapy product composed of natural killer (NK) cells derived from genetically engineered human induced pluripotent stem cells (iPSCs). These NK cells are engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen CD19. The therapy is designed for immunomodulating and antineoplastic activity against CD19-positive B-cell malignancies. Developed by Qihan Biotech, it represents the first gene-edited iPSC-derived cell therapy product approved for clinical trials in China. Its primary indication is for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma and other CD19-positive hematologic cancers[1][2][3][4][5].
- Other names
- allogeneic anti-CD19 CAR-NK cells QN-019a
02
Targets
Beyond the preview
Go deeper on QN-019a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QN-019a.